I agree that just the short time Dr Malan was with QMC
I agree that just the short time Dr Malan was with QMC would be enough for him to understand the nuances of integration of any special QD for biotech applications. QMC would have gained knowledge of his needs in QD and in QMCH adaption to clinical trial capabilities for all stages. One difference would be QMCH would be a distributed, non-centralized DLT with far more flexibility in linking different trials. It could be the center of a clinical trial ecosystem, a very large market itself.
In that sense, I see the move benefiting all parties in creating more products and more need for QMC HEALTHID type software. QMC will not be in the biotech research business but will defer to Innova in that area.
Innova is a better match for him to further develop stem cell based assays and treatments especially as they are in larger quarters and can build labs to suit the work to be done most efficiently, as well as having an existing R&D scientist base. It makes total sense.
I can even see the idea for the move might have come from QMC management itself, rather than Innova because Squires has built a team that does look far into the future. They hired Dr Malan, and saw his best use was at Innova, maybe, and IMO. The move seems to be an amiable one.
QMC loses future clinical research business and perhaps future Malan intellectual properties yet to be patented, depending on what the employment agreement states. That has value, and long story short, makes me think there is an unrevealed quid pro quo negotiated in favor of QMC, just like when ball teams trade players. IOW, I think QMC got something of value in return.
Quantum Materials Corp. (QTMM) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding TSA PreCheck's Impact on Travelers The latest survey reveals some interesting insights about TSA PreCheck, especially concerning the time savings that members experience at security checkpoints. Conducted by Upgraded Points, this enlightening study assessed the experience of over 1,500 travelers to evaluate the true advantages of holding a TSA PreCheck...
Continue Reading
Intermap Technologies Announces New Prospectus Supplement DENVER – Intermap Technologies Corporation (TSX: IMP; OTCQB: ITMSF), a recognized leader in 3D geospatial products and intelligence solutions, has filed a prospectus supplement in the context of a strategically planned public offering. This initiative signifies a promising step forward, with the company aiming to...
Continue Reading
Critical Deadline for Humacyte Investors Approaches As time runs short, investors in Humacyte, Inc. (NASDAQ: HUMA) should pay attention. Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively investigating claims on behalf of investors who have suffered losses exceeding $75,000 due to potential violations in federal securities laws. Understanding Your...
Continue Reading
Empowering Women in Banking: Natalie Bartholomew at Alkami Co:lab Natalie Bartholomew, a highly recognized advocate for women in financial services, will be the featured speaker for the Women in Banking session at Alkami Co:lab 2026. Her expertise and passion are expected to inspire attendees and foster discussions around women's roles in the financial sector. Alkami...
Continue Reading
OPAL Fuels Earnings Report Insights OPAL Fuels OPAL is preparing to release its quarterly earnings report soon, and investors are keenly interested in the results. As the anticipated date for this report approaches, it is essential for investors to stay informed and understand what the expectations are. Projected Earnings Overview Analysts project that OPAL Fuels will...
Continue Reading
